Qelbree is not currently approved or available in Canada. As of now, there is no publicly announced timeline for its potential introduction to the Canadian market.
What is Qelbree?
Qelbree is a medication approved in the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in pediatric patients ages 6 to 17 [1]. It is a novel, non-stimulant medication that works by modulating the activity of voltage-gated sodium and calcium channels [1].
Why isn't Qelbree available in Canada yet?
For a drug to be available in Canada, it must undergo a review and approval process by Health Canada. This typically involves submitting extensive clinical trial data demonstrating the drug's safety and efficacy for its intended use. It is unknown if or when the manufacturer will seek approval for Qelbree in Canada.
How long does drug approval usually take?
The drug approval process can be lengthy and complex. In Canada, the time it takes for Health Canada to review a new drug submission varies depending on the complexity of the submission and the drug's therapeutic area. This process can take many months to several years.
Are there other non-stimulant ADHD medications available in Canada?
Yes, several non-stimulant ADHD medications are available in Canada, including atomoxetine (Strattera) and certain alpha-2 adrenergic agonists like guanfacine extended-release (Intuniv) and clonidine extended-release (Kapvay) [2].
Where can I find information on drug approvals in Canada?
Information on approved drugs and their availability in Canada is maintained by Health Canada. The Drug and Health Product Portal is a resource that lists authorized drugs. For updates on specific medications like Qelbree, it would be necessary to monitor announcements from the manufacturer, Supernus Pharmaceuticals, or Health Canada's official channels [3].
*
**Sources:
[1] https://www.qelbree.com/about-qelbree
[2] https://www.adhdcanada.ca/en/treatment-options/medications
[3] https://www.canada.ca/en/health-canada.html